| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/14/2009 | EP2014660A2 Novel crystalline forms of valacyclovir hydrochloride |
| 01/14/2009 | EP2014657A1 Diaminopyrimidines as modulators for an EP2 receptor |
| 01/14/2009 | EP2014655A2 Etnangien derivatives and their use as antibiotics |
| 01/14/2009 | EP2014653A1 Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| 01/14/2009 | EP2014652A1 Activating agent for peroxisome proliferator activated receptor |
| 01/14/2009 | EP2014651A1 Compounds and methods for modulating Rho GTPases |
| 01/14/2009 | EP2014649A1 Novel amorphous carvedilol dihydrogen phosphate |
| 01/14/2009 | EP2014645A1 Pleuromutilin derivatives and their use as antimicrobials |
| 01/14/2009 | EP2014640A1 Pleuromutilin derivatives |
| 01/14/2009 | EP2014333A1 Use of cooling agents for treatment or prevention of lacrimation or eye burning |
| 01/14/2009 | EP2014304A1 Colon cleansing compositions |
| 01/14/2009 | EP2014303A2 APO-2L receptor agonist and CPT-11 synergism |
| 01/14/2009 | EP2014298A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014292A2 Fenoldopam for treatment of acute renal failure |
| 01/14/2009 | EP2014291A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
| 01/14/2009 | EP2014290A2 Use of tenatoprazole for the treatment of gastroesophageal reflux disease |
| 01/14/2009 | EP2014289A1 Pharmaceutical composition for intracellular acidification with cis-urocanid acid |
| 01/14/2009 | EP2014288A1 Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand |
| 01/14/2009 | EP2014287A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor |
| 01/14/2009 | EP2014286A2 Cremophor free epothilone particles coated with protein for treating cancer |
| 01/14/2009 | EP2014285A1 NPYY5 antagonists |
| 01/14/2009 | EP2014284A1 Pharmaceutical compositions and uses |
| 01/14/2009 | EP2014283A1 Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same |
| 01/14/2009 | EP2014282A2 Treatment of depression |
| 01/14/2009 | EP2014281A1 Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. |
| 01/14/2009 | EP2014274A1 Hydrocarbon compounds and their use |
| 01/14/2009 | EP2014181A2 Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/or alterations of the normal intestinal flora |
| 01/14/2009 | EP2014180A1 Composition useful for the reduction of the cardivascular risk and foods that contain it |
| 01/14/2009 | EP2014179A1 A new use of conjugated linoleic acid |
| 01/14/2009 | EP2013629A1 Methods of diagnosis and treatment of equine laminitis and cushing' s syndrome |
| 01/14/2009 | EP2013626A2 Methods of diagnosing and treating migraine |
| 01/14/2009 | EP2013344A2 Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
| 01/14/2009 | EP2013343A2 SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION |
| 01/14/2009 | EP2013233A2 Use of tm-601 for the diagnosis and treatment of tumors |
| 01/14/2009 | EP2013219A1 Crystalline modification of cefuroximaxetil |
| 01/14/2009 | EP2013218A2 Raf inhibitors and their uses |
| 01/14/2009 | EP2013216A2 Novel spiro [imidazolidine-4, 3' -indole] 2, 2', 5' (1h) triones for treatment of conditions associated with vanilloid receptor 1 |
| 01/14/2009 | EP2013215A2 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1 |
| 01/14/2009 | EP2013214A2 Constrained compounds as cgrp-receptor antagonists |
| 01/14/2009 | EP2013213A2 Constrained compounds as cgrp-receptor antagonists |
| 01/14/2009 | EP2013211A2 Purine derivatives for use as adenosin a2a receptor agonists |
| 01/14/2009 | EP2013210A1 Purine derivatives with activity to the adenosine a2a receptor |
| 01/14/2009 | EP2013209A2 Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists |
| 01/14/2009 | EP2013207A1 Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| 01/14/2009 | EP2013206A1 Pharmaceutical compounds |
| 01/14/2009 | EP2013205A1 Heterocyclic substituted, anellated pyrazole derivative and its uses |
| 01/14/2009 | EP2013204A2 2-aminopyridine analogs as glucokinase activators |
| 01/14/2009 | EP2013201A1 Heterocyclic gpcr agonists |
| 01/14/2009 | EP2013199A1 Adenosine a3 receptor agonists |
| 01/14/2009 | EP2013198A2 Solid-state form of amg 706 and pharmaceutical compositions thereof |
| 01/14/2009 | EP2013197A1 Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
| 01/14/2009 | EP2013196A2 Disubstituted aniline compounds |
| 01/14/2009 | EP2013195A1 Gem-difluoride c-glycopeptide compounds, their preparation and use particularly for preservation of biological materials. |
| 01/14/2009 | EP2013192A1 4-amino-2,6-dimethylphenol compound, process for its preparation and pharmaceutical composition comprising the same |
| 01/14/2009 | EP2013189A1 Dhfr enzyme inhibitors |
| 01/14/2009 | EP2013188A1 Rosuvastatin zinc salt |
| 01/14/2009 | EP2013187A2 Diarylthiohydantoin compounds |
| 01/14/2009 | EP2013186A1 Imidazole derivatives for use as edg-1 antagonists |
| 01/14/2009 | EP2013185A1 Novel compounds |
| 01/14/2009 | EP2013184A1 Sulfonamide compounds useful as edg receptor modulators |
| 01/14/2009 | EP2013183A1 Derivatives of 4-(2-amino-1-hydroxiethyl)phenol as agonists of the beta2 adrenergic receptor |
| 01/14/2009 | EP2013182A2 Aminoquinolones as gsk-3 inhibitors |
| 01/14/2009 | EP2013181A1 Pyridyl compounds |
| 01/14/2009 | EP2013180A1 Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
| 01/14/2009 | EP2013179A1 Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 01/14/2009 | EP2013178A1 Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists |
| 01/14/2009 | EP2013177A1 Dicarboxamide derivatives |
| 01/14/2009 | EP2013175A1 p38 MAP KINASE INHIBITORS |
| 01/14/2009 | EP2013172A1 New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder |
| 01/14/2009 | EP2013171A1 Piperidines and related compounds for treatment of alzheimer s disease |
| 01/14/2009 | EP2013170A1 4-squarylpiperazine derivatives as antiviral agents |
| 01/14/2009 | EP2013169A1 Indole amide derivatives as ep4 receptor antagonists |
| 01/14/2009 | EP2013166A2 N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| 01/14/2009 | EP2013165A1 Diphenylazetidinone derivates possessing cholesterol absor tion inhibitor activit. |
| 01/14/2009 | EP2013163A1 Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
| 01/14/2009 | EP2013016A2 Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| 01/14/2009 | EP2012872A2 Treating cancer using electromagnetic fields in combination with other treatment regimens |
| 01/14/2009 | EP2012808A2 Extracts and methods comprising ganoderma species |
| 01/14/2009 | EP2012807A1 Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders |
| 01/14/2009 | EP2012804A1 Polymer-based anti-cancer agents |
| 01/14/2009 | EP2012803A2 Polymeric compositions and methods of making and using thereof |
| 01/14/2009 | EP2012802A1 Novel drugs for anti-herpes virus treatments |
| 01/14/2009 | EP2012801A2 Gemcitabine combination therapy |
| 01/14/2009 | EP2012800A2 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions |
| 01/14/2009 | EP2012799A2 Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
| 01/14/2009 | EP2012798A2 Use of inositol-tripyrophosphate in treating tumors and diseases |
| 01/14/2009 | EP2012797A2 Novel formulations |
| 01/14/2009 | EP2012796A2 The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
| 01/14/2009 | EP2012795A2 Therapeutic triterpenoids |
| 01/14/2009 | EP2012793A1 Use of a tricyclic compound for preparing a medicine for treating skeletal muscle degeneration |
| 01/14/2009 | EP2012792A1 Use of a compound inducing an increase of free serotonin rate in the body, for preparing a medicine for treating skeletal muscle degeneration |
| 01/14/2009 | EP2012791A2 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors |
| 01/14/2009 | EP2012790A2 Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
| 01/14/2009 | EP2012789A1 Method of treatment of age-related macular degeneration(amd) |
| 01/14/2009 | EP2012788A2 Pre-mixed, ready-to-use iv bolus compositions and methods of use |
| 01/14/2009 | EP2012787A2 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 01/14/2009 | EP2012786A2 Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
| 01/14/2009 | EP2012785A1 Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia |
| 01/14/2009 | EP2012784A1 Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia |